FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 268 filers reported holding FATE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $45,953 | +76.4% | 12,287 | 0.0% | 0.00% | +100.0% |
| Q3 2023 | $26,048 | -76.9% | 12,287 | -48.0% | 0.00% | -75.0% |
| Q2 2023 | $112,545 | +60.7% | 23,644 | +92.4% | 0.00% | +33.3% |
| Q1 2023 | $70,035 | +56379.8% | 12,287 | 0.0% | 0.00% | -40.0% |
| Q4 2022 | $124 | -100.0% | 12,287 | +5.3% | 0.01% | -58.3% |
| Q3 2022 | $262,000 | -12.4% | 11,672 | -3.2% | 0.01% | -7.7% |
| Q2 2022 | $299,000 | -36.0% | 12,058 | 0.0% | 0.01% | -18.8% |
| Q1 2022 | $467,000 | -33.9% | 12,058 | 0.0% | 0.02% | -30.4% |
| Q4 2021 | $706,000 | +5.4% | 12,058 | +6.7% | 0.02% | -4.2% |
| Q3 2021 | $670,000 | -31.7% | 11,304 | 0.0% | 0.02% | -31.4% |
| Q2 2021 | $981,000 | +121.9% | 11,304 | +110.9% | 0.04% | +105.9% |
| Q1 2021 | $442,000 | – | 5,361 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |